- Home
- CLYM vs BYSI Comparison
CLYM vs BYSI Comparison
Compare CLYM & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- BYSI
- Stock Information
- Founded
- CLYM 2018
- BYSI 2010
- Country
- CLYM United States
- BYSI United States
- Employees
- CLYM N/A
- BYSI N/A
- Industry
- CLYM
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- BYSI Health Care
- Exchange
- CLYM NYSE
- BYSI Nasdaq
- Market Cap
- CLYM 83.1M
- BYSI 72.1M
- IPO Year
- CLYM 2021
- BYSI 2017
- Fundamental
- Price
- CLYM $1.19
- BYSI $1.68
- Analyst Decision
- CLYM
- BYSI
- Analyst Count
- CLYM 0
- BYSI 0
- Target Price
- CLYM N/A
- BYSI N/A
- AVG Volume (30 Days)
- CLYM 125.8K
- BYSI 32.9K
- Earning Date
- CLYM 05-19-2025
- BYSI 04-14-2022
- Dividend Yield
- CLYM N/A
- BYSI N/A
- EPS Growth
- CLYM N/A
- BYSI N/A
- EPS
- CLYM N/A
- BYSI N/A
- Revenue
- CLYM N/A
- BYSI N/A
- Revenue This Year
- CLYM N/A
- BYSI N/A
- Revenue Next Year
- CLYM N/A
- BYSI N/A
- P/E Ratio
- CLYM N/A
- BYSI N/A
- Revenue Growth
- CLYM N/A
- BYSI N/A
- 52 Week Low
- CLYM $1.05
- BYSI $0.98
- 52 Week High
- CLYM $10.23
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- BYSI 52.97
- Support Level
- CLYM N/A
- BYSI $1.64
- Resistance Level
- CLYM N/A
- BYSI $2.14
- Average True Range (ATR)
- CLYM 0.00
- BYSI 0.18
- MACD
- CLYM 0.00
- BYSI 0.03
- Stochastic Oscillator
- CLYM 0.00
- BYSI 44.58
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.